Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: A new link between angiogenesis and hyperfibrinolysis?

Translational Research

Volumn 160, Issue 5, 2012, Pages 346-354

  Pawlak, Krystyna ^a   Ulazka, Blanka ^a   Mysliwiec, Michal ^a   Pawlak, Dariusz ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLASMIN; CREATININE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UREA; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD CLOTTING; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FIBRINOLYSIS; HUMAN; HYPERFIBRINOLYSIS; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84867520418     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.04.004     Document Type: Article

References (45)

1. P. Stenvinkel Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease J Int Med 268 2010 456 467
2. V. Menon, A. Gul, and M.J. Sarnak Cardiovascular risk factors in chronic kidney disease Kidney Int 68 2005 1413 1418
3. R.N. Foley, P. Parfrey, and M.J. Samak Clinical epidemiology of cardiovascular disease in chronic renal failure Am J Kidney Dis 32 Suppl 3 1998 S112 S119
4. R. Dubin, M. Cushman, and A.R. Folsom Kidney function and multiple hemostatic markers: cross-sectional associations in the multi-ethnic study of atherosclerosis BMC Nephrology 12 2011 3
5. R. Corti, V. Fuster, and J.J. Badimon Pathogenetic concepts of acute coronary syndromes J Am Coll Cardiol 41 2003 7S 14S
6. V. Toschi, R. Gallo, and M. Lettino Tissue factor modulates the thrombogenicity of human atherosclerotic plaques Circulation 95 1997 594 599
7. R.J. Westrick, P.F. Bodary, Z. Xu, Y.C. Shen, G.J. Broze, and D.T. Eitzman Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice Circulation 103 2001 3044 3046
8. P.E. Morange, C. Bickel, and V. Nicaud Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease. The AtheroGene Study Arterioscler Thromb Vasc Biol 26 2006 2793 2799
9. P.A. Sakkinen, M. Cushman, and B.M. Psaty Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women Arterioscler Thromb Vasc Biol 19 1999 499 504
10. M. Cushman, R.N. Lemaitre, and L.H. Kuller Fibrinolytic activation markers predict myocardial infarction in the elderly: The Cardiovascular Health Study Arterioscler Thromb Vasc Biol 19 1999 493 498
11. M. Gyöngyösi, D. Glogar, and F. Weidinger Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction AM Heart J 147 2004 158 164
12. H.R. Lijnen, and D. Collen Mechanisms of physiological fibrinolysis. Bailliere's clinical hematology 8 1995 Bailliera Tindall London, UK 277-290
13. P.W. Holm, R.H. Slart, C.J. Zeebregts, J.L. Hillebrands, and R.A. Tio Atherosclerotic plaque development and instability: a dual role for VEGF Ann Med 41 2009 257 264
14. B.Q. Shen, D.Y. Lee, K.M. Cortopassi, L.A. Damico, and T.F. Zioncheck Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells J Biol Chem 276 2001 5281 5286
15. M.S. Pepper, N. Ferrara, L. Orei, and R. Montesano Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells Biochem Biophys Res Commun 181 1991 902 906
16. M.E. Kroon, P. Koolwijk, M.A. Vermeer, B. van der Vecht, and V.W. van Hinsbergh Vascular endothelial growth factor enhances the expression of urokinase receptor in human endothelial cells via protein kinase C activation Thromb Haemost 85 2001 296 302
17. A.J. Makin, N.A.Y. Chung, S.H. Silverman, and G.Y.H. Lip Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin Sci 104 2003 397 404
18. A. Migdalski, M. Kotschy, and A. Jawien Tissue factor, tissue factor pathway inhibitor and vascular endothelial growth factor - A in carotid atherosclerotic plaques Eur J Vasc Surg 30 2005 41 47
19. Y.F. Liu, S. Guo, R. Zhao, Y.G. Chen, X.Q. Wang, and K.S. Xu Correlation of vascular endothelial growth factor expression with tumor recurrence and poor prognosis in patients with pNO gastric cancer World J Surg 36 2012 109 117
20. C.S. Chen, C.M. Shih, and G.C. Tseng Vascular endothelial growth factor C as a predictor of early recurrence and poor prognosis of resected stage I non-small cell lung cancer Ann Acad Med Singapore 40 2011 319 326
21. H. Necarda, M. Schmitt, and K. Ulm Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer Cancer Res 54 1994 2900 2907
22. H. Miyake, I. Hara, K. Yamanaka, K. Gohji, S. Arakawa, and S. Kamidono Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer Prostate 39 1999 123 129
23. H. Pedersen, N. Brunner, and D. Francis Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue Cancer Res 54 1994 4671 4675
24. W. Peng, J. Chen, Y. Jiang, Z. Shou, Y. Chen, and H. Wang Prediction of subclinical renal allograft rejection by vascular endothelial growth factor in serum and urine J Nephrol 21 2008 535 542
25. J.J. Roelofs, A.T. Rowshani, and J.G. van der Berg Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection Kidney Int 64 2003 1845 1853
26. F. Gueler, S. Rong, and M. Mengel Renal urokinase-type plasminogen activator (uPA) receptor but not uPA deficiency strongly attenuates ischemia reperfusion injury and acute kidney allograft rejection J Immunol 15 2008 1179 1189
27. M. Kario, T. Matsuo, and M. Matsuo Marked increase of activated factor VII in uremic patients Thromb Haemost 73 1995 763 767
28. M.J. Adams, A.B. Irish, G.F. Watts, R. Oostryck, and G.K. Dogra Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function Thromb Res 123 2008 374 380
29. D. Mezzano, E.O. Pais, and E. Aranda Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis Thromb Haemost 76 1996 312 321
30. K. Pawlak, J. Tankiewicz, M. Mysliwiec, and D. Pawlak Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment Blood Coagul Fibrinolysis 20 2009 590 594
31. T. Ito, T. Niwa, and E. Matsui Fibrinolytic activity in renal disease Clin Chim Acta 36 1972 145
32. D. Mezzano, F. Espana, and O. Panes Increased activation of protein C, but lower plasma levels of free, activated protein C in uraemic patients: relationship with systemic inflammation and haemostatic activation Br J Haematol 113 2001 905 910
33. K. Pawlak, A. Buraczewska-Buczko, M. Mysliwiec, and D. Pawlak Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment Am J Med Sci 339 2010 5 9
34. K. Pawlak, M. Mysliwiec, and D. Pawlak Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure Cytokine 43 2008 98 101
35. National Kidney Foundation K/DOQI: clinical practice guide-lines for chronic kidney disease: evaluation, classification, and stratification Am J Kideney Dis 39 2002 S1 S266
36. A.D. Blann, F.M. Belgore, C.N. McCollum, S. Silverman, P.L. Lip, and G.Y. Lip Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes Clin Sci (Lond) 102 2002 187 194
37. N.A. Chung, C. Lydakis, F. Belgore, F.L. Li-Saw-Hee, A.D. Blann, and G.Y.H. Lip Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease Heart 89 2003 1411 1415
38. K. Abe, M. Shoji, and J. Chen Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor Proc Nat Acad Sci USA 96 1999 8663 8668
39. I.F. Mizukami, N.E. Faulkner, M.R. Gyetko, R.G. Sitrin, and R.F. Todd III Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo Blood 86 1995 203 211
40. P.E. Dekkers, T. ten Hove, A.A. te Velde, S.J. van Deventer, and T. van Der Poll Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia Infect Immun 68 2000 2156 2160
41. G.W. Prager, J.M. Breuss, S. Steurer, J. Mihaly, and B.R. Binder Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells Blood 103 2004 955 962
42. H. Matsuno, O. Kozawa, and N. Yoshimi Lack of α2-antiplasmin promotes pulmonary heart failure via over release of VEGF after acute myocardial infarction Blood 100 2002 2487 2493
43. A. Ahmad, D. Kong, S.H. Sarkar, Z. Wang, S. Banerjee, and F.H. Sarkar Inactivation of uPA and its receptor uPAR by 3, 3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration J Cell Biochem 107 2009 516 527
44. W.H. Tang, H. Friess, and F.F. di Mola Activation of the serine proteinase system in chronic kidney rejection Transplantation 27 1998 1628 1634
45. B. Fuhrman The urokinase system in the pathogenesis of atherosclerosis Atherosclerosis 222 2012 8 14